Swiss National Bank Point Biopharma Global Inc. Transaction History

Swiss National Bank

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$6.67 - $9.71 $16,675 - $24,275	2,500 Added 1.83%	139,366 $929,000
Q1 2023 May 10, 2023	SELL	$6.78 - $8.1 $94,242 - $112,590	-13,900 Reduced 9.22%	136,866 $995,000
Q4 2022 Feb 08, 2023	SELL	$5.72 - $9.78 $49,192 - $84,108	-8,600 Reduced 5.4%	150,766 $1.1 Million
Q3 2022 Nov 09, 2022	BUY	$7.24 - $10.31 $461,912 - $657,778	63,800 Added 66.76%	159,366 $1.23 Million
Q2 2022 Aug 09, 2022	BUY	$5.6 - $9.5 $58,239 - $98,800	10,400 Added 12.21%	95,566 $651,000
Q1 2022 May 09, 2022	BUY	$5.46 - $8.13 $31,668 - $47,154	5,800 Added 7.31%	85,166 $679,000
Q4 2021 Feb 08, 2022	BUY	$4.83 - $9.75 $383,337 - $773,818	79,366 New	79,366 $444,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.